Erection depends largely on the release of nitric oxide (NO) by vascular endothelial cells. 27
Insulin resistance (IR) is a metabolic abnormality that produces endothelial dysfunction 28 characterized by decreased synthesis and release of NO. Aim: To evaluate the effect of 29 treatment with metformin on the response to sildenafil in patients with erectile dysfunction 30 (ED) and IR. Methods: Prospective, randomized, controlled, double-blind placebo study. 31
We included 30 male patients with ED, IR and poor response to sildenafil. Exclusion 32 criteria: pharmacologic, anatomic or endocrine ED, diabetes, prostatic surgery or chronic 33 illnesses. Erectile function was rated according to the International Index of Erectile 34
Function 5 (IIEF-5). IR was measured by HOMA (IR=HOMA ≥ 3). Patients were 35 randomized to receive metformin (n=17) or placebo (n=13). Results: After treatment with 36 metformin, patients with ED showed a significant increase in IIEF-5 score and a significant 37 decrease in HOMA both occurring at months 2 (IIEF-5: 17.0±6.0 vs. 14.3±3.9, p=0.01 and 38 HOMA: 3.9±1.6 vs. 5.5±2.4, p=0.01) to 4 of treatment (IIEF-5: 19.8±3.8 vs. 14.3±3.9, 39 7 141 -Group P (n = 13) used metformin placebo in 2 doses/day (one at lunch and one at dinner) 142 plus sildenafil on demand during 4 months. 143 144 All patients were instructed to take sildenafil between 1 and 2 hours prior to sexual 145 intercourse, and 2 hours after meals. At baseline all patients were taking 100 mg of 146 sildenafil. 147
148
Randomization was performed using a computer generated randomization list that 149 our hospital provides for that purpose. Participants were randomly assigned following 150 simple randomization procedures (computarized random numbers) to 1 of 2 treatment 151 groups. The placebo was prepared with the same matrix as metformin and was packaged in 152 the same way, they were prepacked in boxes with number 1 or 2 for placebo or metformin. 153
The packaging was done by personnel not involved in the delivery of medication to patients. 154
Block randomization was by a computer generated random number list performed by an 155 investigator with no clinical involvement in the trial. Investigators and participants remained 156 masked regarding treatment and trial results. 157
158
The 4-month follow-up of both groups included three visits: basal (pretreatment), 159 month 2 and month 4, where we performed: physical examination, assessment of adherence 160 to treatment, assessment of adverse events, IIEF-5, measurement of blood glucose and 161 insulin levels and HOMA index calculation. Changes in the IIEF-5 score were taken as 162 efficacy criteria for the proposed treatment. In our study, patients using metformin had more adverse events than the placebo 327 group. In all cases, the adverse events were mild, transient, gastrointestinal (diarrhea, 328 bloating, nausea, and abdominal distension) and did not require stopping the treatment. This 329 might be the result of starting with a high dose of metformin without titration. Previous 330 studies from diabetes centers have reported the same adverse gastrointestinal events with the 331 use of metformin, with a significant decrease in frequency when higher dosages begin to be 332 used (Florez et al, 2010; Howlett and Bailey, 1999) . 333 334 To our knowledge, this is the first randomized trial that has been performed using 335 insulin sensitizer agents in patients with ED. Insulin sensitizers, such as metformin, may 336 someday be a part of combination treatment options for men with IR and ED recalcitrant to 337 oral agent therapies. Only 6 patients in the placebo group complete the study, the high drop 338 out was due to lack of therapeutic effect, understandable in a study where the desirable 339 therapeutic effect is so evident (the erectile reponse for intercourse), these and the low 340 number of subjects included are the major limitations of our study. TT (ng/mL) 3.6 ± 1.1 4.1 ± 1.0 0.17 BT (ng/mL) 1.6 ± 0.5 1.7 ± 0.4 0.49 Month 2 27.7 ± 3.3 3.9 ± 1.6 17.0 ± 6.0 
